Company news

Gain Therapeutics, Inc. news in 2025

Gain Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

December 18, 2025

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

December 18, 2025

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

November 20, 2025

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

November 12, 2025

Gain Therapeutics to Present at Neuroscience 2025

October 30, 2025

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

October 16, 2025

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®

October 6, 2025

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

September 23, 2025

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease

September 18, 2025

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

September 4, 2025

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

August 12, 2025

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

July 24, 2025

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

July 16, 2025

Gain Therapeutics Announces Proposed Public Offering

July 15, 2025

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation

June 30, 2025

Gain Therapeutics to Participate in Upcoming Investor Conferences

June 10, 2025

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 29, 2025

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 14, 2025

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

May 12, 2025

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

May 1, 2025

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

April 30, 2025

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

April 10, 2025

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

March 28, 2025

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

March 27, 2025

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

March 14, 2025

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

March 6, 2025

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

January 7, 2025

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

January 6, 2025

Decks in 2025